Clinical trials: Stage II Breast Carcinoma
Metastatic Breast Cancer
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Trastuzumab resistance, which is a common therapeutic challenge in HER2 positive metastatic breast cancer, is not fully understood. Pyrotinib is an oral tyrosine kinase inhibitor targeting EGFR, HER-2 and HER-4 receptors.
- Trial name
- NCT04001621
- Testing
- Pyrotinib combined with capecitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04081389
- Testing
- Celecoxib, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Cognitive/Functional Effects, Recurrent Breast Cancer
Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery
This clinical trial studies vascular and cognitive assessments in patients with breast cancer undergoing chemotherapy after surgery.
- Conditions
- Cognitive/Functional Effects, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT01483196
- Testing
- ultrasound imaging, questionnaire administration, assessment of therapy complications
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Breast Cancer
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
HR+/HER2+（Human epidermal growth factor receptor 2 positive and hormone receptor positive）metastatic breast cancer is a special subtype of HER2+breast cancer.
- Trial name
- NCT04034589
- Testing
- Pyrotinib combined with fulvestrant
- Where
- 2 sites in China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, HER-2 Positive Breast Cancer
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and…
- Conditions
- Breast Cancer, HER-2 Positive Breast Cancer, Effects of Chemotherapy
- Trial name
- NCT01432223
- Testing
- Nab-paclitaxel
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Osaka Medical College
Breast Cancer
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER…
- Trial name
- NCT00234403
- Testing
- gefitinib and fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma, Breast Neoplasms
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.
- Conditions
- Urothelial Carcinoma, Breast Neoplasms, Lung Cancer, Gastric Cancer
- Trial name
- NCT06551896
- Testing
- Pemigatinib
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Triple-Negative Breast Cancer
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast…
- Trial name
- NCT06685796
- Testing
- BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injection
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- BeBetter Med Inc
Breast Cancer
Fluorescence Guided Surgery in Breast Cancer
A need for further investigation for fluorescence image-guided surgery in breast conserving surgery (BCS) has arisen following the results obtained from a phase I feasibility breast cancer trial (BIRDYE study: ABR NL…
- Trial name
- MARGIN (NCT02583568)
- Testing
- Bevacizumab-800CW
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- University Medical Center Groningen
Malignant Pleural Disease, Mesothelioma
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood.
- Conditions
- Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer
- Trial name
- NCT02414269
- Testing
- iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, HR+ / HER2- Advanced Breast Cancer
- Trial name
- NCT05318469
- Testing
- Ivermectin, Balstilmab, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yuan Yuan
Metastatic Breast Cancer
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple…
- Trial name
- NCT06099769
- Testing
- Enzalutamide, Mifepristone, TPC
- Where
- 12 sites in United States
- Volunteers
- 201 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasm
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.
- Trial name
- NCT01221870
- Testing
- Tesetaxel once every 3 weeks, Tesetaxel once weekly
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Genta Incorporated
Breast Cancer
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00232505
- Testing
- cetuximab, carboplatin
- Where
- 14 sites in United States
- Volunteers
- 112 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003927
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Breast Neoplasms
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
The purpose of this study is to assess the efficacy, safety and tolerability of a therapy with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for patients with relapsed or metastatic triple receptor…
- Trial name
- NCT00448305
- Testing
- EndoTAG-1 + paclitaxel, EndoTAG-1, Paclitaxel
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 143 people
- Sponsor
- MediGene
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.
- Trial name
- NCT06178159
- Testing
- Disitamab Vedotin Injection, Pertuzumab Injection, Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Metastatic Breast Cancer
First Line Therapy for Patients With Metastatic Breast Cancer
The purpose of this study is to determine the toxicity and anti-tumor activity of nab-paclitaxel 100mg/m^2 administered weekly in a 4-week cycle as first line therapy to patients with metastatic breast cancer who received taxanes…
- Trial name
- NCT00456846
- Testing
- ABI-007
- Where
- 14 sites in Canada
- Volunteers
- 123 people
- Sponsor
- Celgene
Breast Cancer
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression
- Trial name
- NCT01617668
- Testing
- LCL161, paclitaxel
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 209 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.